In the phase 1b trial, treatment with once-weekly subcutaneous CT-388 led to a statistically significant mean placebo-adjusted weight loss of nearly 20%.
Safety and HbA1c reduction with efsitora alfa dosed once weekly was comparable to both daily insulin degludec and daily insulin glargine, announced Lilly.
New research shows that menstrual irregularity is associated with a higher prevalence of cardiometabolic conditions in women, even in the absence of PCOS.